Sansure Biotech Inc. (688289.SS)
CNY 22.2
(0.0%)
CNY 22.2
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -4.13 Billion CNY | -29.93% |
| 2022 | -3.18 Billion CNY | -21.49% |
| 2021 | -2.62 Billion CNY | -3.37% |
| 2020 | -2.53 Billion CNY | -2457.13% |
| 2019 | -99.16 Million CNY | 21.92% |
| 2018 | -127.01 Million CNY | -218.26% |
| 2017 | -39.9 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | -4 Billion CNY | -2.94% |
| 2024 Q1 | -3.85 Billion CNY | 6.72% |
| 2024 Q2 | -3.87 Billion CNY | -0.46% |
| 2023 Q4 | -4.13 Billion CNY | -20.22% |
| 2023 FY | -4.13 Billion CNY | -29.93% |
| 2023 Q3 | -3.44 Billion CNY | -39.77% |
| 2023 Q1 | -2.42 Billion CNY | 23.73% |
| 2023 Q2 | -2.46 Billion CNY | -1.38% |
| 2022 Q3 | -2.43 Billion CNY | -11.47% |
| 2022 Q2 | -2.18 Billion CNY | 28.76% |
| 2022 Q1 | -3.06 Billion CNY | -16.76% |
| 2022 FY | -3.18 Billion CNY | -21.49% |
| 2022 Q4 | -3.18 Billion CNY | -31.02% |
| 2021 Q4 | -2.62 Billion CNY | -12.25% |
| 2021 Q2 | -3.31 Billion CNY | -34.77% |
| 2021 Q1 | -2.46 Billion CNY | 2.96% |
| 2021 Q3 | -2.33 Billion CNY | 29.58% |
| 2021 FY | -2.62 Billion CNY | -3.37% |
| 2020 Q3 | -767.33 Million CNY | -73.79% |
| 2020 Q4 | -2.53 Billion CNY | -230.47% |
| 2020 Q2 | -441.54 Million CNY | -226.09% |
| 2020 Q1 | -135.4 Million CNY | -36.55% |
| 2020 FY | -2.53 Billion CNY | -2457.13% |
| 2019 Q4 | -99.16 Million CNY | 0.0% |
| 2019 FY | -99.16 Million CNY | 21.92% |
| 2019 Q1 | 127.01 Million CNY | 0.0% |
| 2018 FY | -127.01 Million CNY | -218.26% |
| 2017 FY | -39.9 Million CNY | 0.0% |